Healthcare Stocks on Investing Radars Before Earnings

Seattle Genetics, Inc. (NASDAQ:SGEN) will unveil its latest earnings on Monday, February 13, 2012. The average estimate of analysts is for a loss of 30 cents per share, a narrower loss from the year earlier quarter net loss of 34 cents. During the past three months, the average estimate has moved up from a loss of 34 cents. Between one and three months ago, the average estimate moved up. It has been unchanged at a loss of 30 cents during the last month.

Last quarter, the company came in at net loss of 35 cents per share against a mean estimate of a loss of 46 cents per share, beating estimates after missing them in the previous quarter. In the second quarter, it missed forecasts by 6 cents. On average, analysts predict $39.1 million in revenue this quarter, a rise of more than fourfold from the year ago quarter. Analysts are forecasting total revenue of $83.7 million for the year, a decline of 22.1% from last year’s revenue of $107.5 million.

Competitors to Watch: Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb Co. (NYSE:BMY), Biogen Idec Inc. (NASDAQ:BIIB), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Genzyme Corporation (NASDAQ:GENZ), Micromet Inc. (NASDAQ:MITI), Allos Therapeutics, Inc. (NASDAQ:ALTH), Cephalon, Inc. (NASDAQ:CEPH), Celgene Corporation (NASDAQ:CELG), and ImmunoGen, Inc. (NASDAQ:IMGN).

Health Management Associates, Inc. (NYSE:HMA) will unveil its latest earnings on Monday, February 13, 2012. The average estimate of analysts is for net income of 21 cents per share, a rise of 31.2% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved up from 20 cents. Between one and three months ago, the average estimate moved down. It has risen from 19 cents during the last month. For the year, analysts are projecting profit of 80 cents per share, a rise of 23.1% from last year.

The company’s quarterly results have come in above estimates for the last three quarters. Last quarter, the company booked net income of 19 cents per share versus a mean estimate of profit of 17 cents per share. Analysts are projecting a rise of 17% in revenue from the year-earlier quarter to $1.58 billion.

Competitors to Watch: Community Health Systems (NYSE:CYH), Universal Health Services, Inc. (NYSE:UHS), Tenet Healthcare Corp. (NYSE:THC), HCA Holdings Inc (NYSE:HCA), MedCath Corporation (NASDAQ:MDTH), SunLink Health Systems, Inc. (AMEX:SSY), LifePoint Hospitals, Inc. (NASDAQ:LPNT), Dynacq Healthcare, Inc. (NASDAQ:DYII), Select Medical Hldgs. Corp. (NYSE:SEM), and HEALTHSOUTH Corp. (NYSE:HLS).

Laboratory Corp. of America Holdings (NYSE:LH) will unveil its latest earnings on Friday, February 10, 2012. The average estimate of analysts is for profit of $1.53 per share, a rise of 4.8% from the company’s actual earnings for the same quarter a year ago. The average estimate is the same as three months ago. Between one and three months ago, the average estimate was unchanged. It also has not changed during the last month. Analysts are projecting profit to rise by 5.4% versus last year to $6.30.

Last quarter, the company beat estimates by one cent, coming in at net income of $1.61 a share versus the estimate of profit of $1.60 a share. It marked the fourth straight quarter of beating estimates. Analysts are projecting a rise of 6.2% in revenue from the year-earlier quarter to $1.38 billion.

Competitors to Watch: Quest Diagnostics Inc. (NYSE:DGX), Orchid Cellmark, Inc. (NASDAQ:ORCH), Clarient, Inc. (NASDAQ:CLRT), Bio-Reference Laboratories, Inc. (NASDAQ:BRLI), Psychemedics Corp. (NASDAQ:PMD), MEDTOX Scientific, Inc. (NASDAQ:MTOX), Enzo Biochem, Inc. (NYSE:ENZ) and RadNet Inc. (NASDAQ:RDNT).

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com